Simone Bonazzi, Eva d'Hennezel, Rohan E J Beckwith, Lei Xu, Aleem Fazal, Anna Magracheva, Radha Ramesh, Artiom Cernijenko, Brandon Antonakos, Hyo-Eun C Bhang, Roxana García Caro, Jennifer S Cobb, Elizabeth Ornelas, Xiaolei Ma, Charles A Wartchow, Matthew C Clifton, Ry R Forseth, Bethany Hughes Fortnam, Hongbo Lu, Alfredo Csibi, Jennifer Tullai, Seth Carbonneau, Noel M Thomsen, Jay Larrow, Barbara Chie-Leon, Dominik Hainzl, Yi Gu, Darlene Lu, Matthew J Meyer, Dylan Alexander, Jacqueline Kinyamu-Akunda, Catherine A Sabatos-Peyton, Natalie A Dales, Frédéric J Zécri, Rishi K Jain, Janine Shulok, Y Karen Wang, Karin Briner, Jeffery A Porter, John A Tallarico, Jeffrey A Engelman, Glenn Dranoff, James E Bradner, Michael Visser, Jonathan M Solomon
Malignant tumors can evade destruction by the immune system by attracting immune-suppressive regulatory T cells (Treg) cells. The IKZF2 (Helios) transcription factor plays a crucial role in maintaining function and stability of Treg cells, and IKZF2 deficiency reduces tumor growth in mice. Here we report the discovery of NVP-DKY709, a selective molecular glue degrader of IKZF2 that spares IKZF1/3. We describe the recruitment-guided medicinal chemistry campaign leading to NVP-DKY709 that redirected the degradation selectivity of cereblon (CRBN) binders from IKZF1 toward IKZF2...
February 25, 2023: Cell Chemical Biology